Thank you, the Leigh. our Good all thank of afternoon, used demonstrated to continued standard progress making of platform you disease. Positive the for patients us. results quarter global stages care towards everyone, treat glaucoma and joining across third GX
retina versus front, quarter results financial record an we These sales sales On for prior due to million the in $XX.X U.S. and medical revenues global increase a in Revenues summer third million the reported represent a the slower over increase from a quarter in of quarter $X.X IRIDEX, benefited the quarter seasonally GX comparable is third typically in year. in which holidays. quarter the year. last
our relative of product out to take in for minutes segments like and are beginning next GX cover earlier development the goals business commercial stages we and third quarter this value. highlights each still organization, performance to and few review us and infrastructure our shareholder demonstrate marketing our reps I I'd investments, of laid to the the our year. the early success our Although, onboarding out adoption, as such we long-term building in are growth believe and hiring to of potential new
for retinal the second, treatment for line and As Cyclo first, for GX of DME, treatment glaucoma; for Diabetic product system used retina Edema, of our our of segments: primary business the treatment the GX. line Macular products tears a surgical we Cyclo reminder, Starting quick third detachments. our medical have or three our retina with
GX believe ever in in business in treatment truly is as the noted calls, remain confident that to existing as and the transformational I've I As us, $X alternative billion the for address of prior we opportunity shortcomings market.
and In platform XXXX, GX patients. team for is in probes In of system continuing GX shipped resulting the as we clinics in increasing centers. have customers U.S. offers Our progress late-stage deliver the with U.S., approximately make launch of have lower-cost laser of glaucoma portfolio a and and the a probes. quarter, ophthalmology systems target GX March networks, successful hospital care our solutions to were purchased adding XXX ambulatory institutions to systems, quarter the number record Since disposable multiple in a in we systems to our GX surgery new in XX,XXX early well customers large as that
the form meaningful system to of have rates. segment still In driving we reorder believe grow believe probe I and is improved improved customer addition system a of the business. opportunity after key GX reorders. in follow-up saw growth, sale this of utilization our we utilization We pockets to that probe
from our a we're a in substantial regulatory long-time regarding KOL podium making highlight. of I user highlight We have a recently our the GX more at and and opportunistic penetrating GX globally. sold to to currently One, we in we're like recent model is physicians in KOLs a crowd XX to new year. our institutions. earlier the time first making with our from two And presentation potential, go cadence working relationships of countries, clearance, towards time, markets. have model distributor at these us podium conference with held especially summary, high-touch DOG Japan, of next a and supplementing in with where relationships These is a Two seeing than targeted about controlled particularly participated steps UCSF. made that leverage would with in ESCRS GX sales progress presentation received change the continued are recently enable launch traction the progress more direct that to experience in we in year, in large developing In the glaucoma the close we building of further Germany, And gaining we than installed The nice a taking their our distributor recent sales countries are opportunities. which interest in Japanese GX with generated GX, to At this progress I manager in countries. we is the And their highlighting minute. a the awareness and growing standing-room-only we come as activities. in leading online leading from Berlin. At Tokyo, we base, are will more meeting these where short encouraging. will our we Internationally, support at a into activities are the symposium had XXX Lisbon, that session made decision the technologies JCO interest
GX. also have in Orleans, the the physicians presence our we AAO with with leading their at to week numerous significant New conference a regarding experience Next plan at booth presentations by
the realize speed care, expanded this things. adopter focus we personnel plan As of more new MicroPulse our from of early mainstream I sales opportunity, care. will to the customers we to of believe move benefits of comes on growth, and up towards order to awareness to several standard able technology be our In
to of marketing improve and events support including to the regions. targeted intended industry First, we developing our KOL key presence continue worldwide outreach, at additional many in
will service, opportunities treatment accomplished to our customer improving team care which on procedure and we increasing same, value the our of adoption Second, for communicate of work standard help continue value-based to as of that believe This to be to – improve execution closing to be seek will be to of goal clinical and add a the our solution programs the GX, and consistent our the plan global to our marketplace will procedure. with platform economic And the remains the we we In medicine treat plan we we make key sales offer of glaucoma several our GX the compelling to patients. and glaucoma. education to series deliver by clinical clinical will third, studies. of outcomes, we the specialists believe the to to treatment clinical
increase driven improved up acceptance by was Turning to the of We substantial of as treatment saw which a DME. MicroPulse and of number for to on revenues U.S., global market quarter, a including, retina in products reps our a in a our alternative. medical coming the programs continued marketing third the sales factors treatment during basis new speed
anticipate capital given line product of lumpiness nature We to continue this in equipment this business. quarter-to-quarter the
OUS with revenues the offset detachments. quarters, relatively U.S. dynamics business, which competitive delivers pressure treatment third The at our mature in to with retinal a growth market quarter rate with at our prior saw consistent retina in ongoing turning We decline tears expectations. in pricing with the a a flat overall the Lastly, segment. surgical by and were consistent several for
the turn for call goals I'd Atabak a our XXXX. review the to to to comments additional over highlights regarding recent to few like I financials, make execution Before related
As of strategy. components to current year, beginning we were our laid the out at the there primary two
opportunity I'd commercial minutes to our infrastructure continue progress to to commercial we've the and for new see develop highlight Starting we commercial with GX to expand next to us our expansion like take growing for transformational First, our to the demand The products. on infrastructure. our market platform second, this enabled made. of focus our few new infrastructure recent business. to address constantly
make sales our in the to beginning coming side, meaningful On U.S. speed to and contributions. are the up new reps
clinical the training outcomes. As initiatives, our sales hiring and in process I specialists earlier, we consistent noted ensure also are to provide of additional follow-up support
already in on the Our visibility new team field. our impact is an raising having marketing
participation activities attention. in that events able have have had received replays a ramp leverage to have through and widespread significant and We further been these industry webinars up and in educational webcast
approach awareness in eye of expect this our MicroPulse benefits to continue We treating of technology to disease. the build
new improve quality well improved activities products that reliability while our the features initiatives, continuing product are R&D around product technologies are our development to and existing expected costs. retina repurposing our product benefits and reducing Regarding and advancing by glaucoma line we as as of
making are steady progress more appropriate. look information We sharing when to and forward
by and Affairs. training new I'm at clinical feedback get and that to of product leader our lasers delighted agreed ophthalmic products. team oversee will and ophthalmology has George which senior confident initiatives of for are Board executive of like join the our both Co-founder Abbott with and in that in as to serve Coherent work In Clinical improve OptiMedica, team. clinical call for Marcellino customer We growing his current roles markets. XXXX. and he laser that, Lumenis, his various over role of customer development the a VP also to also turn was enable who Atabak studies base. He member strong of medical at a and at our Directors, in is ophthalmic our of care aesthetic more acquired to ophthalmology technology support to an will utilization specialist company, laser IRIDEX, customer will Marcellino, us was and needs served Dr. a He laser in field us to I'd veteran better surgical a our drive background the information. financial With to new
